INFLAMMATORY DISORDERS



Relevance of erythrocyte sedimentation rate and C-reactive protein in patients with active uveitis

Fahriye Groen-Hakan¹ · Laura Eurelings² · Jan van Laar² · Aniki Rothova¹

Received: 8 May 2018 / Revised: 15 October 2018 / Accepted: 25 October 2018 \odot The Author(s) 2018

Abstract

Purpose To relate erythrocyte sedimentation rates (ESR) and C-reactive protein (CRP) values to different uveitis entisties. **Methods** A retrospective study of patients with a first episode of active uveitis visiting the Erasmus University Medical Center, uveitis clinic, Rotterdam, the Netherlands, was performed. Levels of ESR and CRP were determined within 2 weeks and 1 week after onset of uveitis, respectively. Uveitis had to be of unknown origin at that moment. The specific etiologic groups were related to ESR and CRP values.

Results The majority of patients with uveitis had ESR and/or CRP values within the normal limits and no association of ESR and/ or CRP with the specific cause of uveitis was observed. However, elevation of ESR \geq 60 mm/h and/or CRP \geq 60 mg/L was mostly seen in patients with systemic immune-mediated diseases (8/59, 14% of all with immune-mediated diseases) or systemic infectious causes (7/38, 18% of all infectious uveitis). Patients with ocular toxoplasmosis typically exhibited normal ESR and CRP (9/11, 82%) while patients with endogenous endophthalmitis had elevated ESR and/or CRP in 6/7, 86%. Sarcoidosisassociated uveitis showed predominantly elevated ESR (13/24, 54%; range 20–59 mm/h in 11/13, 85%). Human immunodeficiency virus–positive patients had more often elevated ESR values when compared to the remainder of patients (9/11, 82% vs. 64/163, 39%, 18%, *P* = 0.009). The cause of uveitis was established in 19/20 (95%) of patients with ESR \geq 60 mm/h and/or CRP \geq 60 mg/L.

Conclusions The majority of patients with first attack of uveitis had ESR and CRP within the normal limits. Elevated levels of ESR and CRP reflected systemic involvement and high levels of both values were associated with established uveitis cause.

Keywords Erythrocyte sedimentation rate · C-reactive protein · Uveitis · Diagnostics

Introduction

Uveitis is an intraocular inflammation of multiple causes, which may result in permanent visual loss [1-4]. Erythrocyte sedimentation rate (ESR) and C-reactive protein

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00417-018-4174-7) contains supplementary material, which is available to authorized users.

(CRP), both non-specific markers of inflammation, are usually included in the initial diagnostic workup. However, the clinical value of these parameters in the adult uveitis population is not known. Earlier investigations showed that ESR and CRP are within the normal range in a majority of patients with anterior uveitis [5]. In contrast, a recent report on juvenile idiopathic arthritis (JIA)-associated uveitis in a pediatric population showed that elevated ESR predicted the development of uveitis in patients with JIA [6]. However, it remains debatable whether ESR and CRP have any diagnostic value in evaluation of uveitis in adult patients having a first uveitis attack of unexplained origin.

Herein, we investigate the values of ESR and CRP during the first episode of active uveitis, determined within a short period after the onset in adult patients and relate the results to specific etiologic categories and clinical characteristics of uveitis.

Fahriye Groen-Hakan f.groen@erasmusmc.nl

¹ Department of Ophthalmology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands

² Department of Internal Medicine and Department of Immunology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands

Materials and methods

The Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines were used to ensure the reporting of this observational study and this study followed the Tenets of the Declaration of Helsinki [7].

We conducted a retrospective cross-sectional study at the ophthalmology department of the Erasmus Medical Center (Rotterdam, the Netherlands). All medical records of patients referred with new uveitis of unknown origin investigated between 2010 and 2017 were reviewed and 174 patients were identified who fulfilled our inclusion criteria. The onset of uveitis was defined as the first time active inflammation was documented by an ophthalmologist. ESR had to be determined ≤ 2 weeks and CRP values ≤ 1 week after the onset uveitis (as ESR normalizes within weeks and CRP levels within 7 days after resolution of tissue injury) [8]. Exclusion criteria included age less than 18 years and patients with first mild anterior uveitis episode as these patients do not undergo diagnostic screening according to our guidelines. The ESR and CRP values were arbitrarily stratified to three subgroups (normal ESR < 20 mm/h, elevated ESR between 20 and 60 mm/h, highly elevated ESR \geq 60 mm/h and normal CRP <10 mg/L (as defined in our laboratory), elevated CRP between 10 and 60 mg/L and highly elevated CRP \geq 60 mg/L).

The following data were extracted from patients' records: age, gender, localization of uveitis, laterality, and human immunodeficiency virus (HIV) status. All immunosuppressive medications as well as co-morbidities were registered. Definitive anatomical classification was determined according to the Standardization of Uveitis Nomenclature (SUN) Working Group, by reviewing the whole follow-up period [9].

The cause of uveitis was determined after the diagnostic examinations were completed. The diagnosis of definitive ocular sarcoidosis was given to patients that had histologically proven evidence and in all other cases; the criteria from the International Workshop on Ocular Sarcoidosis (IWOS) were used [10]. For the diagnosis of tuberculosis (TB)-associated uveitis, a positive culture for mycobacteria in any fluid/tissue sample was needed. Patients with a positive tuberculin skin test (Mantoux test) or interferon gamma release assay (IGRA) test with otherwise unexplained uveitis and no other indications of active tuberculosis were labeled as of unknown origin. All other specific diagnoses were performed according to current diagnostic criteria [10–16].

All statistical analyses were performed using SPSS software (version 22.0, Chicago, IL, USA) and a P value of < 0.05 was considered statistically significant. Specific groups were categorized as mentioned above and compared with each other according to gender, anatomical localization of uveitis, age, and etiology. Continuous variables were described by mean and range, categorical variables with proportions, and compared using the Mann-Whitney U test. Categorical

variables were compared using the chi-square test or Fisher's exact test.

Results

The results of ESR and CRP measurements are shown in Table 1. Specific diagnoses in our cohort are depicted in the Supplemental Table. A majority of patients was diagnosed with associated non-infectious systemic diseases (59/174, 34%) and had non-anterior uveitis (141/174, 81%). Slight female preponderance was observed (96/174, 55%).

Immunosuppressive medication (required for other causes than uveitis) was used by 17/174, 10% patients. Patients suffering from diabetes mellitus (DM) and patients using immunosuppressive medication more often had elevated ESR values (P = 0.018 for both, chi-square test), compared to the remainder of patients. No significant differences in ESR and CRP levels were found for gender, race, localization, or laterality of uveitis (all P values > 0.05, chi-square test). Furthermore, elevated values of ESR and/or CRP were not significantly associated with any of the etiologic categories.

Concordance and discrepancies between ESR and CRP are depicted in Table 2. A majority of patients had both ESR and CRP values within the normal limits (91/174, 52%). Elevation of only one of the parameters was seen in 50/174, 29%. Elevated levels of both parameters were found in 33/174, 19% patients.

The median ESR and CRP of patients with uveitis of established cause were higher than the median ESR and CRP of patients with unknown uveitis (17.0 mm/h, range 1–120 mm/h vs. 11.0 mm/h, range 1–140 mm/h for ESR and 3.4 mg/L, range 0.4–262.0 mg/L vs. 1.9 mg/L, range 0.3–229.0 mg/L for CRP; P = 0.015 for both, Mann-Whitney U test).

Out of 20 patients with either ESR \geq 60 mm/h and/or CRP \geq 60 mg/L, the cause of uveitis could be determined in 19/20. Fifteen had either non-infectious systemic disease or systemic infection, which was also a cause of uveitis (Table 3). The remaining five patients had uveitis limited to the eye, but had a concurrent systemic disorder, which explained their highly elevated ESR and/or CRP but was not related to the cause of uveitis (such as multiple myeloma in a patient with infectious uveitis).

A majority of patients with infectious uveitis had ESR and CRP values within the normal limits (17/38, 45%) or only ESR ≥ 20 mm/h (14/38, 37%), see Table 2. Discrepant results were more often noted in this group (17/38, 45% vs. 33/136, 24% *P* = 0.024, chi-square test). Patients with toxoplasmosis exhibited normal ESR values in 9/11, 82%, and all had CRP values within the normal limits. Patients with endogenous endophthalmitis exhibited CRP ≥ 10 mg/L in 5/7, 71%.

Table 1	Erythrocyte sedimentation rate and (C-reactive protein of patients	s with a first episode of activ	ve uveitis of unknown cause

	Total $N = 174$	ESR ^a			CRP ^a		
		< 20 (N=101)	20–59 (N=57)	$\geq 60 \ (N = 16)$	<10 (N=131)	10–59 (N=33)	$\geq 60 \ (N=10)$
Total	174	101/174 (58%)	57/174 (33%)	16/174 (9%)	131/174 (75%)	33/174 (19%)	10/174 (6%)
Diabetes mellitus	17/174 (10%)	5/17 (29%)	9/17 (53%)	3/17 (18%)	12/17 (71%)	5/17 (29%)	0
Immune suppressive medication ^b	17/174 (10%)	5/17 (29%)	7/17 (41%)	5/17 (29%)	12/17 (71%)	2/17 (12%)	3/17 (18%)
Human immunodeficiency virus positivity ^c Anatomical localization	11/174 (6%)	2/11 (18%)	5/11 (45%)	4/11 (36%)	10/11 (91%)	0	1/11 (9%)
Anterior	33/174 (19%)	18/33 (55%)	10/33 (30%)	5/33 (15%)	23/33 (70%)	8/33 (24%)	2/33 (6%)
Intermediate	2/174 (1%)	1/2 (50%)	1 (50%)	0	2/2 (100%)	0	0
Posterior	45/174 (26%)	32/45 (71%)	12/45 (27%)	1/45 (2%)	37/45 (82%)	8/45(18%)	0
Panuveitis	86/174 (49%)	48/86 (56%)	30/86 (35%)	8/86 (9%)	65/86 (76%)	15/86(17%)	6/86 (7%)
Scleritis	8/174 (5%)	2/8 (25%)	4/8 (50%)	2/8 (25%)	4/8 (50%)	2/8 (25%)	2/8 (25%)
Non-infectious systemic disease	59/174 (34%)	33/59 (56%)	20/59 (34%)	6/59 (10%)	39/59 (66%)	14/59 (24%)	6/59 (10%)
Infectious uveitis	38/174 (22%)	20/38 (53%)	11/38 (29%)	7/38 (18%)	31/38 (82%)	4/38 (11%)	3/38 (8%)
Established clinical entity	24/174 (14%)	14/24 (58%)	8/24 (33%)	2/24 (8%)	17/24 (71%)	7/24 (29%)	0
Unknown	53/174 (30%)	34/53 (64%)	18/53 (34%)	1/53 (2%)	44/53 (83%)	8/53 (15%)	1/53 (2%)

ESR erythrocyte sedimentation rate, CRP C-reactive protein

^a ESR had to be determined < 2 weeks of onset, CRP within < 1 week of onset

^b Indicated for other causes than uveitis

^c HIV was tested in 62 patients, out of which 11/62 (18%) were found positive

Patients with non-infectious uveitis commonly had ESR and CRP values that were both within the normal limits (28/59, 47%; Table 2). If elevated (N=31), the parameters were most often elevated simultaneously (15/31, 48%). Of the patients with HLA B27-associated uveitis without systemic involvement, 2/8, 25% exhibited CRP \geq 10 mg/L and 1/8, 13% had both ESR \geq 20 mm/ h and CRP \geq 10 mg/L. Two patients had HLA B27-associated uveitis with systemic involvement of which one had high elevation of CRP \geq 60 mg/L and ESR \geq 20 mm/h and the other exhibited normal values. Sarcoidosis-associated uveitis showed a predominantly elevated ESR (13/24, 54%; in the range between 20 and 59 mm/h 11/13, 85%), while CRP was most often normal (17/24, 71%). Systemic involvement in sarcoidosis patients (hilar lymphadenopathy as seen on chest imaging) was present in 21/ 24 (88%); however, in only 4/21 (19%) of these, treatment was required.

The HIV was positive in 11/62, 18% tested patients. HIVpositive patients had more often elevated ESR values when compared to the remainder of patients (9/11, 82% vs. 64/163, 39%, P = 0.009, chi-square test). An infectious cause for uveitis was found in 9/11, 82% HIV-positive patients, out of which 4/9, 44% had CMV retinitis and 4/9, 44% had syphilitic uveitis. ESR ≥ 60 mm/h together with HIV positivity was observed in 4/11, 36% (2 with CMV retinitis, one with syphilitic uveitis, and one with sarcoidosis-associated uveitis). Only one of the HIV-positive patients exhibited normal values of both ESR and CRP; this patient was diagnosed with CMV retinitis.

Discussion

In this retrospective, cross-sectional study, the majority of patients with a first active episode of uveitis of unknown origin presented with normal ESR and CRP values. Moreover, no significant relationship between the levels of these biomarkers and specific causes of uveitis was found.

Earlier investigations of ESR and CRP in uveitis patients also demonstrate normal values in a majority of patients with anterior uveitis, but none of these previous studies defined the time window in which ESR and CRP were determined in relation to the onset of uveitis, while both biomarkers are susceptible for changes within short periods [5, 8, 17]. Biomarkers like ESR and CRP are commonly assessed during the diagnostic workup of new uveitis patients for potential detection of infections or systemic immune-mediated disease-causing uveitis [1–4, 18–21]. Elevated levels of ESR are due to a higher plasma protein levels (e.g., fibrinogen, gamma globulins) and CRP is an acute phase protein released after tissue injury caused by infections or other sources of inflammation [8, 22].

Though a majority of patients with infectious uveitis in the present study exhibited normal ESR and CRP values, increased values were predominantly encountered in systemic infections. The high levels of ESR and CRP were found in patients with endogenous endophthalmitis, an ocular inflammation that occurs concurrently with bacteremia. In contrast, these inflammatory parameters were nearly always normal in

CPP < 10 mgL and ESA		Total $M = 174$	Concordant results ESR and CRP ^a	RP^{a}	Discrepant results ESR and CRP ^a	۲Pa
Age at over of rectis (pero). Mean (e.S.D) $4Sk (\pm 17.1)$ $4G1 (\pm 17.2)$ $5G1 (\pm 1.2)$ $5G1 (\pm 1.2)$ $4G1 (\pm 2.0.7)$ Attend mean $3S174 (109)$ $5S3 (58)$ $SS3 (58)$			CRP < 10 mg/L and ESR < 20 mm/h N= 91	ESR $\ge 20 \text{ mm/h}$ and CRP $\ge 10 \text{ mg/L}$ $N = 33$	ESR $\geq 20 \text{ mm/h}$ but CRP < 10 mg/L $N = 40$	$CRP \ge 10 \text{ mg/L but ESR}$ < 20 mm/h N = 10
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Age at onset of uveitis (years) Mean (±SD)	45.8 (±17.1)	43.1 (±17.3)	5.9 (±15.6)	51.7 (± 15.9)	46.6 (± 20.7)
Attent or enclose 2114 (19) 16.3 (48) 8.33 (44) 7.33 (18) 2.33 (66) Performation controls 2174 (26) 12.3 (66) 233 (66) <t< td=""><td>Localization</td><td></td><td></td><td></td><td></td><td></td></t<>	Localization					
$ \begin{array}{c cccc} \mathematic volume (1, 2, 1, 1, 1, 2, 1, 2, 2, 2, 1, 2, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2,$	Anterior uveitis	33/174 (19%)	16/33 (48%)	$\frac{8}{33}(24\%)$	7/33 (21%)	2/33 (6%)
Present news 8(174, 6%) 2945 (6%) 353 (1%)	Intermediate uvertis	2/174(1%)	1/2 (50%)	0	1/2(50%)	0
Rancetis Bit (34) Total (35) Total (36)	Posterior uveitis	45/174 (26%)	29/45 (64%)	5/45 (11%)	8/45 (18%)	3/45 (7%)
$ \begin{array}{c cccc} Set (55) & S(14) (56) & I(3(4)) & S(13(6)) & S(13(6)) & S(13(6)) & S(13(6)) & S(13(6)) & I(3(13)) \\ Larching & S(174(45)) & S(174(5)) & I(3(13)) & S(13(6)) & S(13($	Panuveitis	86/174 (49%)	44/86 (51%)	17/86(20%)	21/86(24%)	4/86 (5%)
	Scleritis	8/174 (5%)	1/8 (13%)	3/8 (38%)	3/8 (38%)	1/8 (13%)
	Laterality					
$ \begin{array}{c} \label{eq:constraints} & \begin{tabular}{lllllllllllllllllllllllllllllllllll$	Unilateral Difetend	83/174 (48%) 01/174 (52%)	43/83 (52%) 18/01 (53%)	15/83(18%)	20/83 (24%)	5/83 (6%)
Franks Strands Strands <thstrands< th=""> <thstrands< th=""> <ths< td=""><td>Duateiai Gender</td><td>(017C) 4/1/16</td><td>(0/.CC) 16/0+</td><td>(0/.07) 16/01</td><td>(0/.77) 16/07</td><td>(01.C) 16/C</td></ths<></thstrands<></thstrands<>	Duateiai Gender	(017C) 4/1/16	(0/.CC) 16/0+	(0/.07) 16/01	(0/.77) 16/07	(01.C) 16/C
Mole 773 (35%) 1773 (35%) 1773 (35%) 1773 (35%) 578 (6%) 578 (6%) Rue Causain 10174 (6%) 59110 (5%) 5710 (5%) 578 (6%)	Females	96/174 (55%)	50/96 (52%)	16/96 (17%)	25/96 (26%)	5/96 (5%)
Rate Bar Bar </td <td>Males</td> <td>78/174 (45%)</td> <td>41/78 (53%)</td> <td>17/78 (22%)</td> <td>15/78 (19%)</td> <td>5/78 (6%)</td>	Males	78/174 (45%)	41/78 (53%)	17/78 (22%)	15/78 (19%)	5/78 (6%)
Cancesian 110/174 (65%) 32010 (26%) 22110 (21%) 6110 (26%) 6101 (65%) Nor-Cancesian 64174 (57%) 3264 (50%) 1164 (17%) 11764 (17%) 6110 (26%) 6101 (65%) Nor-infectors systemic disease 59714 (24%) 2593 (45%) 1159 (19%) 559 (6%) 22310 (20%) Riscollancors 2593 (47%) 10024 (65%) 2510 (20%) 1253 (56%) 223 (6%) 2231 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 223 (6%) 233 (6%) 233 (6%) 234 (6%) 234 (6%) 232 (6%) 233 (6%) 234 (6%) 233 (6%) 234 (6%) 233 (6%) 234 (6%) 233 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) 234 (6%) <td>Race</td> <td></td> <td>~</td> <td>~</td> <td>~</td> <td>~</td>	Race		~	~	~	~
Non-Cancesian 64/174 (37%) 3264 (50%) 11/64 (17%) 17/64 (27%) 464 (6%) Non-infectious systemic disease 59/174 (34%) 3264 (50%) 11/64 (17%) 17/64 (27%) 464 (6%) Non-infectious systemic disease 59/174 (34%) 20/39 (47%) 10/34 (32%) 55/9 (36%) 55/9 (36%) Miscellancous ⁴ 10/35 (17%) 10/34 (32%) 21/3 (25%) 21/3 (25%) 22/3 (25%) 11/3 (26%) 22/3 (36%) 11/3 (46%) 10/3 (45%) 22/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) 2/3 (25%) <td>Caucasian</td> <td>110/174(63%)</td> <td>59/110 (54%)</td> <td>22/110 (20%)</td> <td>23/110 (21%)</td> <td>6/110 (5%)</td>	Caucasian	110/174(63%)	59/110 (54%)	22/110 (20%)	23/110 (21%)	6/110 (5%)
Non-infectious systemic disease $9/174(34\%)$ $28/9(47\%)$ $15/9(25\%)$ $11/9(19\%)$ $559(8\%)$ $123(29(3\%)$ $123(9(3\%)$ $123(9(3\%)$ $123(9(3\%)$ $123(9(3\%)$ $123(9(3\%)$ $123(9(3\%)$ $123(9(3\%)$ $123(3(3\%)$	Non-Caucasian	64/174 (37%)	32/64 (50%)	11/64(17%)	17/64 (27%)	4/64 (6%)
Non-intections systemic disease $39/174$ (34%) $2/859$ (37%) $5/559$ (37%) $7/24$ (39%) $5/59$ (36%) $7/24$ (39%) $1/224$ (45%) $1/224$ (47%)						
Sarcolosis 23/59 (47%) 0.024 (47%) 0.024 (45%	Non-infectious systemic disease	59/174 (34%)	28/59 ($47%$)	15/59 (25%)	11/59 (19%)	5/59 (8%)
HLA B27-essectated tverts 1035 (17%) 6/10 (69%) 2/10 (20%) 0.210 (20%) 2/20 (30%) Miscellaneous ⁶ 25/9 (42%) 12/25 (48%) 7/25 (28%) 0 2/31 (45%) 2/35 (6%) 2/31 (6%) 2/35 (Sarcoidosis	24/59 (41%)	10/24 (42%)	6/24 (25%)	7/24 (29%)	1/24 (4%)
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	HLA B27-associated uvertis	10/59 (17%)	6/10 ($60%$)	2/10 (20%)	0	2/10(20%)
Infectious $38/174 (22\%)$ $1738 (45\%)$ $4.38 (11\%)$ $14738 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $338 (37\%)$ $337 (33\%)$ $372 (33\%)$ $373 (33\%)$ 37	Miscellaneous ^c	25/ 59 (42%)	12/25 (48%)	7/25 (28%)	4/25 (16%)	2/25 (8%)
Toxoplasmosis Trophamosis Toxoplasmosis Tox	Infections	38/174 (22%)	17/38 (45%)	4/38 (110%)	(326) (37%)	(%)38(80%)
Endogrous endophthalmits 736 (18%) 177 (14%) 27 (29%) 177 (14%) 377 (43%)Miscellaneous ⁴ 2038 (13%) 172 (13%) 172 (14%) 377 (14%) 377 (14%) 377 (14%)Miscellaneous ⁴ 2038 (13%) 172 (14%) 120 (10%) 1120 (15%) 1120 (15%) 1024 (4%)Miscellaneous ⁴ 23173 (14%) 1324 (14%) 1234 (14%) 1024 (14%) 1024 (14%)Miscellaneous ⁴ 23173 (14%) 1324 (14%) 1024 (14%) 1024 (14%) 1024 (14%)ESR erythrocyte sedimentation rate. RP C-reactive protein. SD standard deviation. HLA $B27$ human leukocyte antigen $B27$ 424 (17%) 1123 (11%) 1024 (14%)ESR had to be determined 2 weeks of onset. CRP within <1 week of onset	Toxonlasmosis	11/38 (29%)	9/11 (82%)	0	2/11 (18%)	0
Miscellancoust2038 (53%)720 (33%)720 (35%)220 (10%)11/20 (55%)0Esublished clinical entity $24174 (14\%)$ $1334 (54\%)$ $624 (25\%)$ $1224 (7\%)$ $1224 (4\%)$ Esublished clinical entity $23/174 (30\%)$ $33/53 (62\%)$ $8/53 (15\%)$ $11/53 (21\%)$ $10/24 (4\%)$ Est had to be determined <	Endogenous endophthalmitis	7/38 (18%)	1/7 (14%)	2/7 (29%)	1/7(14%)	3/7 (43%)
Esublished clinical entity $24/174 (14\%)$ $13/24 (54\%)$ $6/24 (25\%)$ $4/24 (17\%)$ $1/24 (47\%)$ $1/24 (47\%)$ Unknown $53/174 (30\%)$ $33/53 (62\%)$ $6/24 (25\%)$ $4/24 (17\%)$ $1/24 (47\%)$ $1/23 (25\%)$ <i>ESR</i> erythrocyte sedimentation rate. <i>CRP</i> C-reactive protein. <i>SD</i> standard deviation. <i>HLA B27</i> human leukocyte antigen B27 $4/24 (17\%) (15\%) (21\%)$ $1/53 (21\%)$ $1/53 (25\%)$ <i>ESR</i> had to be determined < 2 weeks of onset. CRP within < 1 week of onset	;Miscellaneous ^d	20/38 (53%)	7/20 (35%)	2/20 (10%)	11/20 (55%)	0
Unknown $53/174 (30\%)$ $33/53 (62\%)$ $8/53 (15\%)$ $11/53 (21\%$	Established clinical entity ^e	24/174 (14%)	13/24 $(54%)$	6/24 (25%)	4/24 (17%)	1/24 (4%)
 <i>ESR</i> erythrocyte sedimentation rate, <i>CRP</i> C-reactive protein, <i>SD</i> standard deviation, <i>HLA B27</i> human leukocyte antigen B27 ^a ESR had to be determined < 2 weeks of onset, CRP within < 1 week of onset ^b 17/24 (71%) of sarcoidosis patients was biopsy confirmed ^b 17/24 (71%) of sarcoidosis patients with Vogt-Koyanagi-Harada syndrome (N = 6), multiple sclerosis (N = 4), Behçet's disease (N = 3), inflammatory bowel disease (N = 3), granulomatorsis with polyangiitis (N = 2), acute disseminated encephalomyelitis (N = 1), Kikuchi disease (N = 3), inflammatory bowel disease (N = 3), granulomatosis with polyangiitis (N = 1). ^c Including varicella-zoster virus (N = 5), cytomegalovirus (N = 4), herpes simplex virus (N = 3), nubella virus (N = 2), bartonella (N = 1), systemic lupus erythematosus (N = 1), systemic vasculitis not onchrvites expecified (N = 1) ^d Including varicella-zoster virus (N = 5), cytomegalovirus (N = 3), birdshot chorioretinopathy (N = 2), toxic uveitis (N = 2), systemic lupus erythematosus (N = 1). ^e Including varicella-zoster virus (N = 5), cytomegalovirus (N = 1), Fuchs heterochronic uveitis syndrome (N = 1), untersite (N = 1), purtscher-like retinopathy (N = 1), Fuchs heterochronic uveitis syndrome (N = 1), nunctate inner choriodopathy (N = 1), purtscher-like retinopathy (N = 1), Fuchs heterochronic uveitis syndrome (N = 1), nunctate inner choriodopathy (N = 1), conta sobsected to be caused by bacillus Calmette-Outinin intraveiscial immunherany for bladder causer (N = 1). Caust disease (N = 1), caust dystrophy (N = 1), uveitis suspected to be caused by bacillus Calmette-Outinin intraveiscial immunherany for bladder causer (N = 1). Coust disease (N = 1), caust dystrophy (N = 1), caust dystrophy (N = 1). Coust disease (N = 1). 	Unknown	53/174 (30%)	33/53 (62%)	8/53 (15%)	11/53 (21%)	1/53 (2%)
 <i>EXR</i> erythrocyte sedumentation rate, <i>CRP</i> C-reactive protein, <i>JD</i> standard deviation, <i>HLA B2/</i> human leukocyte antigen <i>B2/</i> <i>EXR</i> had to be determined < 2 weeks of onset, CRP within < 1 week of onset ^b 17/24 (71%) of sarcoidosis patients was biopsy confirmed ^b 17/24 (71%) of sarcoidosis patients with Vogt-Koyanagi-Harada syndrome (<i>N</i> = 6), multiple sclerosis (<i>N</i> = 4), Behçer's disease (<i>N</i> = 3), inflammatory bowel disease (<i>N</i> = 3), granulomatosis with polyangitits (<i>N</i> = 2), reactive arthritis with uveitis (<i>N</i> = 2), acute disseminated encephalomyelitis (<i>N</i> = 1), Kikuchi disease (<i>N</i> = 1), relapsing polychondritis (<i>N</i> = 1), systemic lupus erythematosus (<i>N</i> = 1), systemic vasculitis not otherwise specified (<i>N</i> = 1) ^d Including varicella-zoster virus (<i>N</i> = 5), cytomegalovirus (<i>N</i> = 4), herpes simplex virus (<i>N</i> = 3), rubella virus (<i>N</i> = 2), bartonella (<i>N</i> = 1), tuberculosis (<i>N</i> = 1), systemic vasculitis not otherwise specified (<i>N</i> = 1) ^e Including varicella-zoster virus (<i>N</i> = 5), cytomegalovirus (<i>N</i> = 1), Ficks heterochronic uveitis syndrome (<i>N</i> = 1), punctate inner (<i>N</i> = 1), macular dystrophy (<i>N</i> = 1), uveitis suspected to be caused by bacillus Calmette-Guérin intravesical immunoherany for bladder cancer (<i>N</i> = 1), conton wool soots (<i>N</i> = 1). 						
 ^a ESR had to be determined <2 weeks of onset, CRP within <1 week of onset ^b 17/24 (71%) of sarcoidosis patients was biopsy confirmed ^c Including patients with Vogt-Koyanagi-Harada syndrome (N = 6), multiple sclerosis (N = 4), Behçet's disease (N = 3), inflammatory bowel disease (N = 3), granulomatosis with polyangiitis (N = 2), recactive arthritis with uveits (N = 2), acute disseminated encephalomyelitis (N = 1), Kikuchi disease (N = 1), relapsing polychondritis (N = 1), systemic lupus erythematosus (N = 1), systemic vasculitis not otherwise specified (N = 1) ^d Including varicella-zoster virus (N = 5), cytomegalovirus (N = 4), herpes simplex virus (N = 3), rubella virus (N = 2), toxic uveitis (N = 1), tuberculosis (N = 1) ^e Including patients with acute multifocal posterior placoid pigment epitheliopathy (N = 3), birdshot chorioretinopathy (N = 2), toxic uveitis (N = 2), post-traumatic uveitis (N = 2), sympathetic ophthalmia (N = 1), serpiginous choroidopathy (N = 1), purtscher-like retinopathy (N = 1), Fuchs heterochromic uveitis syndrome (N = 1), uveitis suspected to be caused by bacillus Calmette-Guérin lintravesical immunotherary for bladder cancer (N = 1), cotton wool soots (N = 1). Coats disease (N = 1) 	<i>ESR</i> erythrocyte sedimentation rate, <i>CRP</i> C-	reactive protein, SU star	idard deviation, $HLA B27$ human l	eukocyte antigen B27		
 ^o 17/24 (71%) of sarcoidosis patients was biopsy confirmed ^o 17/24 (71%) of sarcoidosis patients was biopsy confirmed ^c Including patients with Vogt-Koyanagi-Harada syndrome (<i>N</i> = 6), multiple sclerosis (<i>N</i> = 4), Behçet's disease (<i>N</i> = 3), inflammatory bowel disease (<i>N</i> = 3), granulomatosis with polyangiitis (<i>N</i> = 2), reactive arthritis with uveitis (<i>N</i> = 2), acute disseminated encephalomyelitis (<i>N</i> = 1), Kikuchi disease (<i>N</i> = 1), relapsing polychondritis (<i>N</i> = 1), systemic lupus erythematosus (<i>N</i> = 1), systemic vasculitis not otherwise specified (<i>N</i> = 1) ^d Including varicella-zoster virus (<i>N</i> = 5), cytomegalovirus (<i>N</i> = 4), herpes simplex virus (<i>N</i> = 3), rubella virus (<i>N</i> = 2), bartonella (<i>N</i> = 1), tuberculosis (<i>N</i> = 1) ^d Including patients with acute multifocal posterior placoid pigment epitheliopathy (<i>N</i> = 3), birdshot chorioretinopathy (<i>N</i> = 2), toxic uveitis (<i>N</i> = 2), post-traumatic uveitis (<i>N</i> = 2), sympathetic ophthalmia (<i>N</i> = 1), purtscher-like retinopathy (<i>N</i> = 1), Fuchs heterochromic uveitis syndrome (<i>N</i> = 1), uveitis suspected to be caused by bacillus Calmette-Guérin lymphoma (<i>N</i> = 3), macular drusen (<i>N</i> = 1), macular dystrophy (<i>N</i> = 1), uveitis suspected to be caused by bacillus Calmette-Guérin intravesical immunotherary for bladder cancer (<i>N</i> = 1). cotton wool soots (<i>N</i> = 1). Coast disease (<i>N</i> = 1) 	^a ESR had to be determined < 2 weeks of on	set, CRP within < 1 wee	ek of onset			
^c Including patients with Vogt-Koyanagi-Harada syndrome (<i>N</i> =6), multiple sclerosis (<i>N</i> =4), Behcet's disease (<i>N</i> =3), inflammatory bowel disease (<i>N</i> =3), granulomatosis with polyangiitis (<i>N</i> =2), reactive arthritis with uveitis (<i>N</i> =2), acute disseminated encephalomyelitis (<i>N</i> =1), Kikuchi disease (<i>N</i> =1), relapsing polychondritis (<i>N</i> =1), systemic lupus erythematosus (<i>N</i> =1), systemic vasculitis not otherwise specified (<i>N</i> =1) ^d Including varicella-zoster virus (<i>N</i> =5), cytomegalovirus (<i>N</i> =4), herpes simplex virus (<i>N</i> =3), rubella virus (<i>N</i> =2), bartonella (<i>N</i> =1), tuberculosis (<i>N</i> =1) ^d Including patients with acute multifocal posterior placoid pigment epitheliopathy (<i>N</i> =3), birdshot chorioretinopathy (<i>N</i> =2), toxic uveitis (<i>N</i> =2), post-traumatic uveitis (<i>N</i> =2), sympathetic ophthalmia (<i>N</i> =1), serpiginous choroidopathy (<i>N</i> =1), purtscher-like retinopathy (<i>N</i> =1), Fuchs heterochromic uveitis syndrome (<i>N</i> =1), muctate inner choroidopathy (<i>N</i> =1). The masquerade syndromes including lymphoma (<i>N</i> =3), macular drusen (<i>N</i> =2), human immunodeficiency virus-related microangiopathy (<i>N</i> =1), macular dystrophy (<i>N</i> =1), uveitis suspected to be caused by bacillus Calmette-Guérin intravesical immunotherary for bladder cancer (<i>N</i> =1). conton wool spots (<i>N</i> =1). Coast disease (<i>N</i> =1).	^b 17/24 (71%) of sarcoidosis patients was bic	opsy confirmed				
^d Including varicella-zoster virus ($N = 5$), cytomegalovirus ($N = 4$), syphilis ($N = 4$), herpes simplex virus ($N = 3$), rubella virus ($N = 2$), bartonella ($N = 1$), tuberculosis ($N = 1$) ^e Including patients with acute multifocal posterior placoid pigment epitheliopathy ($N = 3$), birdshot chorioretinopathy ($N = 2$), toxic uveitis ($N = 2$), post-traumatic uveitis ($N = 2$), sympathetic ophthalmia ($N = 1$), purtscher-like retinopathy ($N = 1$), Fuchs heterochromic uveitis syndrome ($N = 1$), punctate inner choroidopathy ($N = 1$), purtscher-like retinopathy ($N = 1$), Fuchs heterochromic uveitis syndrome ($N = 1$), punctate inner choroidopathy ($N = 1$). The masquerade syndromes including lymphoma ($N = 3$), macular drusen ($N = 2$), human immunodeficiency virus-related microangiopathy ($N = 1$), macular dystrophy ($N = 1$), uveitis suspected to be caused by bacillus Calmette-Guérin intravesical immunotherary for bladder cancer ($N = 1$). cotton wool soots ($N = 1$). Coast disease ($N = 1$)	^c Including patients with Vogt-Koyanagi-Ha reactive arthritis with uveitis $(N = 2)$, acute di otherwise specified $(N = 1)$	rada syndrome $(N = 6)$, isseminated encephalom	multiple sclerosis $(N = 4)$, Behçet' yelitis $(N = 1)$, Kikuchi disease $(N =$	s disease $(N = 3)$, inflammatory 1), relapsing polychondritis $(N = 1)$	bowel disease $(N=3)$, granulomate = 1), systemic lupus erythematosus (seis with polyangiitis $(N = 2)$, $N = 1$), systemic vasculitis not
^e Including patients with acute multifocal posterior placoid pigment epitheliopathy ($N = 3$), birdshot choricretinopathy ($N = 2$), toxic uveitis ($N = 2$), post-traumatic uveitis ($N = 2$), sympathetic ophthalmia ($N = 1$), punctate inter choroidopathy ($N = 1$). The masquerade syndromes including lymphoma ($N = 3$), macular dystrophy ($N = 1$), punctate inner choroidopathy ($N = 1$). The masquerade syndromes including lymphoma ($N = 3$), macular dystrophy ($N = 1$), uveitis suspected to be caused by bacillus Calmette-Guérin intravesical immunotherany for bladder cancer ($N = 1$). Coats disease ($N = 1$). Coats disease ($N = 1$).	^d Including varicella-zoster virus $(N=5)$, cvt	some alovirus $(N = 4)$. s	vnhilis ($N = 4$). hernes simplex viru	s $(N=3)$. rubella virus $(N=2)$.	partonella $(N = 1)$. tuberculosis $(N = 1)$	1)
(N = 1), serpiginous choroidopathy $(N = 1)$, purtscher-like retinopathy $(N = 1)$, Fuchs heterochromic uveitis syndrome $(N = 1)$, punctate inner choroidopathy $(N = 1)$. The masquerade syndromes including lymphoma $(N = 3)$, macular drusen $(N = 2)$, human immunodeficiency virus-related microangiopathy $(N = 1)$, macular dystrophy $(N = 1)$, uveitis suspected to be caused by bacillus Calmette-Guérin intravesical immunotherary for bladder cancer $(N = 1)$. conton wool spots $(N = 1)$. Coast disease $(N = 1)$	^e Including patients with acute multifocal pos	sterior placoid pigment e	pitheliopathy $(N = 3)$, birdshot choi	ioretinopathy $(N = 2)$, toxic uvei	itis ($N = 2$), post-traumatic uveitis (N	= 2), sympathetic ophthalmia
intraversial immunotherary for bladder cancer ($N = 1$). conton wool spots ($N = 1$). Coast disease ($N = 1$). Coast disease ($N = 1$). Coast disease ($N = 1$).	(N = 1), serpiginous choroidopathy $(N = 1)$, p hymethema $(N = 3)$ macular driven $(N = 2)$.	burtscher-like retinopathy human immundeficier	N = 1, Fuchs heterochromic uver $N = 1$, $N = 1$	tis syndrome $(N = 1)$, punctate it $(M = 1)$ meaning distrophy $(M = 1)$	nner choroidopathy ($N = 1$). The mas - 1) musicile curvedtad to be conceed	querade syndromes including
	intravesical immunotherapy for bladder canc	the initial multiplication $V = 1$), cotton wool	spots $(N=1)$. Coats disease $(N=1)$	(1) machina uyanopiny (1)	- 1), avenus suspected to be caused	by vacinus cannous-ducini

🖄 Springer

	Erythrocyte sedimentation rate \geq 60 mm/h and/or C-reactive protein \geq 60 mg/L (N =20) ^a
Associated systemic disease	 2 Sarcoidosis 3 Reactive arthritis 1 Granulomatosis with polyangiitis, 1 Relapsing polychondritis 1 Behçet's disease
Infectious disease	 3 Endogenous endophthalmitis 2 Cytomegalovirus retinitis 1 Herpes simplex retinitis^b 1 Varicella-zoster anterior uveitis^b 1 Syphilis 1 Tuberculosis
Clinical entity	1 Masquerade syndrome ^b 1 Post-traumatic uveitis ^b
Unknown	1 ^b

 Table 3
 Patients exhibiting highly elevated erythrocyte sedimentation rate and/or C-reactive protein

 a 10 patients had ESR \geq 60 mm/h, 4 patients had CRP \geq 60 mg/L, and 6 patients both had ESR \geq 60 mm/h and CRP \geq 60 mg/L

^b 5 patients with disease limited to the eye had some other explanation for high elevation of ESR and/or CRP, namely multiple myeloma complicated with varicella-zoster uveitis (N=1), sepsis in herpes simplex–associated uveitis (N=1), inflammatory bowel disease with masquerade syndrome of drusen (N=1), post-operative infection after orthopedic surgery in a patient with post-traumatic uveitis (N=1), and a patient with fever, cachexia, and uveitis of unknown origin (N=1)

patients with ocular toxoplasmosis, an intracellular parasite. Reactivation of these dormant parasites within the eye is not being accompanied by any systemic activity.

In HIV patients, the common hyperimmunoglobulinemia causes elevation of ESR (rather than a direct infectious trigger causing release of fibrinogen). In our series, highly elevated ESR was often seen in HIV-positive patients, and therefore, it might be therefore worthwhile to determine HIV status in patients with uveitis of unknown origin and unexplained high ESR [23]. Patients using immunosuppressive medications and those suffering from DM had more often elevated ESR values and the yield of these tests is therefore lower in these patients.

Elevated levels of ESR and CRP are common in systemic sarcoidosis patients, specifically in sarcoidosis-associated arthritis and erythema nodosum compared to other clinical presentations [24, 25]. Half of the patients with ocular sarcoidosis, however, had both normal ESR and CRP, which might reflect mild (or lack of) systemic involvement at the moment of onset of first uveitis attack [26]. This is also illustrated in the current series, where the majority of patients had very mild extraocular involvement which might also explain their predominantly normal ESR and CRP values.

In this study, follow-up measurements of ESR and/or CRP were not available, and consequently, we do not have information about the highest levels of ESR and CRP reached in individual patients. Including the highest levels of ESR and CRP could possibly expose some associations, which were not found in the present study. In addition, the changes of ESR and/or CRP might change in individual patients and might be associated with impeding uveitis activity. However, our main goal was to determine the diagnostic value of these parameters during the first stage of uveitis after presentation. Data on body mass index, which can influence the ESR and CRP values, were not available in our patients [27].

In conclusion, our study reflects that presence of uveitis alone is not sufficient to cause elevation of ESR and/or CRP as a majority of patients with a first uveitis episode had ESR and CRP values within the normal limits. In patients with highly elevated ESR and/or CRP, the presence of a systemic disease is very likely, and in consequence, the cause of uveitis is being established in a vast majority of cases.

Funding This research was supported by Abbvie Netherlands.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study (retrospective study), formal consent is not required.

Disclaimer The sponsor had no role in the design or conduct of this research.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Groen F, Ramdas W, de Hoog J et al (2016) Visual outcomes and ocular morbidity of patients with uveitis referred to a tertiary center during first year of follow-up. Eye (Lond) 30(3):473–480
- 2. Tsirouki T, Dastiridou A, Symeonidis C et al (2018) A focus on the epidemiology of uveitis. Ocul Immunol Inflamm 26(1):2–16
- Miserocchi E, Fogliato G, Modorati G et al (2013) Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol 23(5):705– 717
- Acharya NR, Tham VM, Esterberg E et al (2013) Incidence and prevalence of uveitis results from the Pacific ocular inflammation study. JAMA Ophthalmol 131(11):1405–1412
- Marsh JD, Markowitz BB (2012) Erythrocyte sedimentation rate and C-reactive protein in anterior uveitis Available from:http://iovs. arvojournals.org/article.aspx?articleid=2359946.[accessed 2017 24-08-2017]
- Haasnoot AJW, van Tent-Hoeve M, Wulffraat NM et al (2015) Erythrocyte sedimentation rate as baseline predictor for the development of uveitis in children with juvenile idiopathic arthritis. Am J Ophthalmol 159(2):372–377

- von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349
- Jain S, Gautam V, Naseem S (2011) Acute-phase proteins: as diagnostic tool. J Pharm Bioallied Sci 3(1):118–127
- Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516
- Herbort CP, Rao NA, Mochizuki M et al (2009) International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 17(3):160–169
- 11. Rosenbaum JT (2017) New developments in uveitis associated with HLA B27. Curr Opin Rheumatol 29(4):298–303
- Okada AA, Stanford M, Tabbara K (2012) Ancillary testing, diagnostic/classification criteria and severity grading in Behcet disease. Ocul Immunol Inflamm 20(6):387–393
- Levinson RD, Brezin A, Rothova A et al (2006) Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am J Ophthalmol 141(1):185–187
- DeBoer JH, Verhagen C, Bruinenberg M et al (1996) Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am J Ophthalmol 121(6):650–658
- Snyder DA, Tessler HH (1980) Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 90(1):69–75
- Crawford CM, Igboeli O (2013) A review of the inflammatory chorioretinopathies: the white dot syndromes. ISRN Inflamm 2013:783190

- 17. Paul S (1963) Erythrocyte sedimentation rate in uveitis a critical analysis. Indian J Ophthalmol 11(1):9–12
- Hooper C, McCluskey P (2008) Intraocular inflammation: its causes and investigations. Curr Allergy Asthma Rep 8(4):331–338
- Rosenbaum JT, Wernick R (1990) Selection and interpretation of laboratory tests for patients with uveitis. Int Ophthalmol Clin 30(4): 238–243
- Rosenbaum JT (1990) An algorithm for the systemic evaluation of patients with uveitis: guidelines for the consultant. Semin Arthritis Rheum 19(4):248–257
- Wade NK, Kevin MD, F.R.C.P.C. et al (2000) Diagnostic testing in patients with ocular inflammation. Int Ophthalmol Clin 40(2):37– 54
- 22. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update (vol 111, pg 1805, 2003). J Clin Investig 112(2):299–299
- 23. Lowe DM (2010) The erythrocyte sedimentation rate in HIV: a neglected parameter? AIDS 24(18):2773–2775
- Shorr AF et al (2000) Osseous disease in patients with pulmonary sarcoidosis and musculoskeletal symptoms. Respir Med 94(3):228– 232
- 25. Greenberg G, James DG, Feizi T et al (1964) Serum-proteins in sarcoidosis. Lancet 2(7373):1313–1315
- Edelsten C, Pearson A, Joynes E et al (1999) The ocular and systemic prognosis of patients presenting with sarcoid uveitis. Eye 13: 748–753
- Samocha-Bonet D, Lichtenberg D, Tomer A et al (2003) Enhanced erythrocyte adhesiveness/aggregation in obesity corresponds to low-grade inflammation. Obes Res 11(3):403–407